Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Deferred Tax (2022 - 2024)

Historic Long-Term Deferred Tax for Theravance Biopharma (TBPH) over the last 5 years, with Q4 2024 value amounting to $2.4 million.

  • Theravance Biopharma's Long-Term Deferred Tax fell 9945.67% to $2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 9945.67%. This contributed to the annual value of $2.4 million for FY2024, which is 9945.67% down from last year.
  • Latest data reveals that Theravance Biopharma reported Long-Term Deferred Tax of $2.4 million as of Q4 2024, which was down 9945.67% from $447.3 million recorded in Q4 2023.
  • Over the past 5 years, Theravance Biopharma's Long-Term Deferred Tax peaked at $447.3 million during Q4 2023, and registered a low of $2.4 million during Q4 2024.
  • Over the past 3 years, Theravance Biopharma's median Long-Term Deferred Tax value was $440.7 million (recorded in 2022), while the average stood at $296.8 million.
  • In the last 5 years, Theravance Biopharma's Long-Term Deferred Tax soared by 148.57% in 2023 and then plummeted by 9945.67% in 2024.
  • Over the past 3 years, Theravance Biopharma's Long-Term Deferred Tax (Quarter) stood at $440.7 million in 2022, then rose by 1.49% to $447.3 million in 2023, then tumbled by 99.46% to $2.4 million in 2024.
  • Its Long-Term Deferred Tax stands at $2.4 million for Q4 2024, versus $447.3 million for Q4 2023 and $440.7 million for Q4 2022.